Frederick Kinder retired in July, 2019. Before retiring, Frederick was Global Head of Oncology and ImmunoOncology (OIO) Research Project Management at Novartis Institutes for Biomedical Research (NIBR). The primary role of this position was to ensure that productivity goals (speed and quality) were met or exceeded through oversight of lead optimization and candidate profiling activities through IND-enabling studies. This included managing the interface with development line functions, and effective communication of progress/issues within NIBR OIO. Frederick received his B.S. in chemistry at James Madison University (1984) and Ph.D. in medicinal chemistry at the S.U.N.Y. at Buffalo (1989). After completing postdoctoral research in synthetic organic chemistry at Emory University (1989-1990), he joined the Radiosynthesis Department at Sandoz Pharmaceuticals Corporation in January 1991. In 1992, Frederick was hired as the first chemist in the newly created Sandoz Oncology Department (later Novartis Oncology following the merge with CIBA in 1996). The research focus on the majority of his projects from 1992 – 2002 was design, synthesis, and biological evaluation of anti-tumor natural products. Frederick was the leader of several teams including the bengamide analogue and discodermolide project teams. Both project teams advanced drug candidates to the clinic. In 2002, Frederick began PJM activities as Research Representative of an Early Project Development Team that managed all Oncology projects from early preclinical development to Clinical Proof of Concept. Frederick has held his current position since 2004.